Xinnate is a pioneering pharmaceutical company focused on developing advanced therapies for complex skin conditions using immune-modulating peptides. The company is currently conducting an ambitious research and clinical program for its lead candidate, TCP 25, which includes a Phase 1b clinical study in patients with Epidermolysis Bullosa (EB). This rare and severe disorder causes fragile, blistering skin, leading to chronic wounds. Xinnate's technology aims to control the presence of microbes and manage inflammatory responses to promote healing. The company plans to move into late-stage clinical development and commercialization in partnership with leading pharmaceutical companies. Xinnate operates in the growing market of wound care and skin inflammation, targeting both healthcare providers and patients. The business model involves developing and licensing its proprietary therapies, generating revenue through partnerships and eventual product sales.

Keywords: immune-modulating peptides, Epidermolysis Bullosa, chronic wounds, skin inflammation, clinical trials, pharmaceutical partnerships, wound care, microbial control, inflammatory response, advanced therapies.